Ph 2 Study of Triheptanoin for Tx of Long-Chain Fatty Acid Oxidation Disorder

三庚酸甘油酯治疗长链脂肪酸氧化障碍的二期研究

基本信息

项目摘要

Title: Phase 2 Triheptanoin for Tx of Long-Chain Fatty Acid Oxidation Disorder Abstract: Fatty acid oxidation disorders are a family of rare inherited diseases affecting an estimated 1:9000 infants. The recent addition of the fatty acid oxidation disorders to the expanded newborn screening panel in the United States has led to the early diagnosis and treatment of this group of disorders. Presymptomatic treatment through newborn screening has decreased episodes of metabolic decompensation and nearly eliminated mortality. However, patients with a long-chain fatty acid oxidation disorders experience long-term complications such as recurrent rabdomyolysis with or without cardiomyopathy. The prevalence of this sub-group of patients with long-chain fatty acid oxidation is unknown but it is estimated to affect approximately 1000 individuals or less in the United States. Novel treatments for these diseases have lagged behind our diagnostic capabilities. We propose to test a novel treatment hypothesized to increase citric acid cycle intermediates and maximize energy production. This randomized clinical trial will examine the efficacy of triheptanoin supplementation (a heptanoate triglyceride) to treat humans with long-chain FAO disorders. Subjects with a long-chain fatty acid oxidation disorder will be randomly assigned to one of two groups: medium chain triglyceride (MCT) supplementation, the current standard of care, or triheptanoin supplementation for four months. After 4 months we will test the effects of supplement treatment on total energy expenditure, the response to a moderate intensity treadmill exercise test, cardiac function and long-chain fatty acid oxidation capacity. The goal of the project is to determine if triheptanoin therapy has a therapeutic advantage over conventional treatment for long-chain fatty acid oxidation disorders.
标题:用于治疗长链脂肪酸氧化障碍的2期三庚酸甘油酯 摘要: 脂肪酸氧化障碍是一种罕见的遗传性疾病, 1:9000婴儿最近增加的脂肪酸氧化障碍, 美国新生儿筛查小组的扩大导致了早期诊断 和治疗这组疾病的方法。通过新生儿进行症状前治疗 筛查减少了代谢失调的发生, mortality.然而,患有长链脂肪酸氧化障碍的患者 长期并发症,如复发性横纹肌溶解, 心肌病该亚组患者的长链脂肪酸患病率 氧化是未知的,但据估计,影响约1000人或更少 在美国这些疾病的新疗法已经落后于我们的 诊断能力。我们建议测试一种新的治疗方法, 柠檬酸循环中间体和最大限度地提高能源生产。这项随机临床 试验将检查三庚酸甘油酯补充剂(一种庚酸甘油三酯)的功效 来治疗人类的长链粮农组织疾病。长链脂肪酸受试者 氧化障碍将被随机分配到两组之一:中链 甘油三酯(MCT)补充剂、当前标准治疗或三庚酸甘油酯 补充四个月。4个月后,我们将测试补充剂的效果 治疗对总能量消耗,对中等强度跑步机的反应 运动试验、心功能和长链脂肪酸氧化能力。的目标 该项目旨在确定三庚酸甘油酯治疗是否具有治疗优势, 用于长链脂肪酸氧化障碍的常规治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Melanie B Gillingham其他文献

Melanie B Gillingham的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Melanie B Gillingham', 18)}}的其他基金

Exploring the pathophysiology and treatment of LCHADD retinopathy
探索 LCHADD 视网膜病变的病理生理学和治疗
  • 批准号:
    10470841
  • 财政年份:
    2021
  • 资助金额:
    $ 37.92万
  • 项目类别:
Exploring the pathophysiology and treatment of LCHADD retinopathy
探索 LCHADD 视网膜病变的病理生理学和治疗
  • 批准号:
    10672942
  • 财政年份:
    2021
  • 资助金额:
    $ 37.92万
  • 项目类别:
Exploring the pathophysiology and treatment of LCHADD retinopathy
探索 LCHADD 视网膜病变的病理生理学和治疗
  • 批准号:
    10276791
  • 财政年份:
    2021
  • 资助金额:
    $ 37.92万
  • 项目类别:
The Natural History of LCHAD Retinopathy
LCHAD 视网膜病变的自然史
  • 批准号:
    10311473
  • 财政年份:
    2019
  • 资助金额:
    $ 37.92万
  • 项目类别:
The Natural History of LCHAD Retinopathy
LCHAD 视网膜病变的自然史
  • 批准号:
    10533334
  • 财政年份:
    2019
  • 资助金额:
    $ 37.92万
  • 项目类别:
The Natural History of LCHAD Retinopathy
LCHAD 视网膜病变的自然史
  • 批准号:
    10017307
  • 财政年份:
    2019
  • 资助金额:
    $ 37.92万
  • 项目类别:
Role of Fatty Acid Oxidation Defects in Insulin Sensitivity
脂肪酸氧化缺陷在胰岛素敏感性中的作用
  • 批准号:
    8883308
  • 财政年份:
    2015
  • 资助金额:
    $ 37.92万
  • 项目类别:
Ph 2 Study of Triheptanoin for Tx of Long-Chain Fatty Acid Oxidation Disorder
三庚酸甘油酯治疗长链脂肪酸氧化障碍的二期研究
  • 批准号:
    8178808
  • 财政年份:
    2011
  • 资助金额:
    $ 37.92万
  • 项目类别:
Ph 2 Study of Triheptanoin for Tx of Long-Chain Fatty Acid Oxidation Disorder
三庚酸甘油酯治疗长链脂肪酸氧化障碍的二期研究
  • 批准号:
    8466310
  • 财政年份:
    2011
  • 资助金额:
    $ 37.92万
  • 项目类别:
Diet-Induced Insulin Resistance in a Murine Fatty Acid Oxidation Disorder
小鼠脂肪酸氧化紊乱中饮食诱导的胰岛素抵抗
  • 批准号:
    8081734
  • 财政年份:
    2010
  • 资助金额:
    $ 37.92万
  • 项目类别:

相似国自然基金

相似海外基金

Techno-economic Feasibility Study of ClimaHtech innovative clean maritime solutions
ClimaHtech 创新清洁海事解决方案的技术经济可行性研究
  • 批准号:
    10098100
  • 财政年份:
    2024
  • 资助金额:
    $ 37.92万
  • 项目类别:
    Collaborative R&D
HAIRCYCLE: a pilot study to explore and test regenerative, local, bio-based and circular models for human hair waste
HAIRCYCLE:一项试点研究,旨在探索和测试人类毛发废物的再生、局部、生物基和循环模型
  • 批准号:
    AH/Z50550X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.92万
  • 项目类别:
    Research Grant
(Un)Fair inequality in the labor market: A global study
(Un)劳动力市场的公平不平等:一项全球研究
  • 批准号:
    MR/X033333/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.92万
  • 项目类别:
    Fellowship
Expanding syphilis screening among pregnant women in Indonesia using the rapid dual test for syphilis & HIV with capacity building: The DUALIS Study
使用梅毒快速双重检测扩大印度尼西亚孕妇梅毒筛查
  • 批准号:
    MR/Y004825/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.92万
  • 项目类别:
    Research Grant
Norway. Neuropeptide origins; study of neuropeptide functions in choanoflagellates
挪威。
  • 批准号:
    BB/X018512/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.92万
  • 项目类别:
    Research Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 37.92万
  • 项目类别:
    Standard Grant
RII Track-4: NSF: Fundamental study on hydrogen flow in porous media during repetitive drainage-imbibition processes and upscaling for underground energy storage
RII Track-4:NSF:重复排水-自吸过程中多孔介质中氢气流动的基础研究以及地下储能的升级
  • 批准号:
    2327317
  • 财政年份:
    2024
  • 资助金额:
    $ 37.92万
  • 项目类别:
    Standard Grant
Collaborative Research: EAGER: The next crisis for coral reefs is how to study vanishing coral species; AUVs equipped with AI may be the only tool for the job
合作研究:EAGER:珊瑚礁的下一个危机是如何研究正在消失的珊瑚物种;
  • 批准号:
    2333604
  • 财政年份:
    2024
  • 资助金额:
    $ 37.92万
  • 项目类别:
    Standard Grant
Collaborative Research: RUI: Continental-Scale Study of Jura-Cretaceous Basins and Melanges along the Backbone of the North American Cordillera-A Test of Mesozoic Subduction Models
合作研究:RUI:北美科迪勒拉山脊沿线汝拉-白垩纪盆地和混杂岩的大陆尺度研究——中生代俯冲模型的检验
  • 批准号:
    2346565
  • 财政年份:
    2024
  • 资助金额:
    $ 37.92万
  • 项目类别:
    Standard Grant
EAGER: Innovation in Society Study Group
EAGER:社会创新研究小组
  • 批准号:
    2348836
  • 财政年份:
    2024
  • 资助金额:
    $ 37.92万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了